Mylan Reaffirms Commitment To Brand Business Growth Despite King Setback
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will continue to explore acquisition opportunities, CEO Coury says, noting King was not "the only option." Mylan is not yet discussing whether it will launch and market nebivolol on its own or seek a partner for the cardiovascular agent; J&J holds a "right to consent" to any partner.
You may also be interested in...
Mylan's Nebivolol Is "Approvable" At FDA
The beta blocker's user fee date had been extended by three months following submission of additional analysis. Mylan expects the anti-hypertensive to be the cornerstone of its brand division.
Mylan's Nebivolol Is "Approvable" At FDA
The beta blocker's user fee date had been extended by three months following submission of additional analysis. Mylan expects the anti-hypertensive to be the cornerstone of its brand division.
Mylan's Pursuit Of King Ends; King Says It's Ready To Go It Alone
"Significant enhancements" in commercial operations and business development organizations will allow King to grow as a standalone company, the firm says. Mylan and King announce termination of their proposed merger one day before the "walk-away" date.